Want to see BIOQ full AI Analyst Report?
Top Page
Bioqual
(OTC:BIOQ)
Select Model
Select Model
Rating:42Neutral
Price Target:
$31.00
▼(-8.82% Downside)
Action:Reiterated
Date:05/30/26
The score is primarily held down by weak financial performance, especially declining revenue and profitability, with additional pressure from bearish technical trends. Valuation adds little support because earnings are negative and no dividend yield is provided.
Positive Factors
Specialized NHP-focused CRO services
Bioqual's niche expertise in non-human primate models creates high technical and regulatory barriers to entry, supporting durable demand from vaccine and therapeutic developers. This specialization fosters long-term client stickiness and pricing power for complex preclinical studies.
Negative Factors
Declining revenue and margins
Three years of shrinking revenue and a recent negative gross profit indicate structural demand or pricing challenges and weak cost absorption. Persistent top-line decline undermines margin recovery and long-term profitability unless new contracts or higher-margin work materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized NHP-focused CRO services
Bioqual's niche expertise in non-human primate models creates high technical and regulatory barriers to entry, supporting durable demand from vaccine and therapeutic developers. This specialization fosters long-term client stickiness and pricing power for complex preclinical studies.
Read all positive factors
Bioqual (BIOQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.50M
Dividend YieldN/A
Average Volume (3M)223.00
Price to Earnings (P/E)―
Beta (1Y)-0.20
Revenue Growth-13.57%
EPS Growth41.93%
CountryUS
Employees278
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.38
Shares Outstanding893,838
10 Day Avg. Volume0
30 Day Avg. Volume223
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.11
Price to Sales (P/S)0.82
P/FCF Ratio14.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bioqual Business Overview & Revenue Model
Company Description
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans nume...
Bioqual Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Aug 2024 | Aug 2023 | May 2023 | Aug 2021 | Aug 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.35M | 48.87M | 58.59M | 62.66M | 66.15M | 57.68M |
| Gross Profit | -2.96M | -1.90M | 7.43M | 12.60M | 13.01M | 13.97M |
| EBITDA | 1.35M | 509.61K | 3.03M | 6.97M | 14.76M | 13.07M |
| Net Income | -1.24M | -1.05M | 483.48K | 835.55K | 5.26M | 6.33M |
Balance Sheet | ||||||
| Total Assets | 71.77M | 57.12M | 56.59M | 61.32M | 63.34M | 53.42M |
| Cash, Cash Equivalents and Short-Term Investments | 13.29M | 17.85M | 15.59M | 7.28M | 2.18M | 7.72M |
| Total Debt | 33.48M | 16.54M | 3.59M | 18.61M | 18.72M | 14.62M |
| Total Liabilities | 36.75M | 20.96M | 18.94M | 23.70M | 25.67M | 19.89M |
| Stockholders Equity | 35.02M | 36.15M | 37.65M | 37.61M | 37.67M | 33.53M |
Cash Flow | ||||||
| Free Cash Flow | 5.94M | 2.71M | 8.76M | 5.99M | -4.57M | -2.26M |
| Operating Cash Flow | 6.28M | 2.94M | 9.36M | 8.23M | 313.36K | 2.15M |
| Investing Cash Flow | -6.75M | -238.78K | -597.13K | -2.24M | -4.73M | -3.70M |
| Financing Cash Flow | 0.00 | -447.21K | -447.21K | -894.42K | -1.12M | -983.86K |
Bioqual Technical Analysis
Negative
34.00
Price Trends
33.75
Negative
34.55
Negative
36.21
Negative
Market Momentum
-0.05
Positive
20.36
Positive
46.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Negative. The current price of 34 is above the 20-day moving average (MA) of 33.74, above the 50-day MA of 33.75, and below the 200-day MA of 36.21, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 20.36 is Positive, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOQ.
Bioqual Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $29.50M | -23.91 | -3.46% | ― | -13.57% | 41.93% | |
| ― | ― | ― | ― | ― | ― | ― | |
66 Neutral | $54.43M | -45.06 | -8.49% | ― | 28.04% | 43.26% | |
61 Neutral | $322.86M | -8.98 | -788.19% | ― | 34.46% | 43.48% | |
52 Neutral | $14.25M | -0.32 | -71.38% | ― | 10.03% | 91.68% | |
42 Neutral | $4.63M | -0.13 | 74.16% | ― | 86.32% | 21.31% |
* Healthcare Sector Average
BIOQ
Bioqual
34.00
-10.10
-22.90%
NOTV
Inotiv
―
―
―
VNRX
VolitionRX
0.50
-12.63
-96.18%
PRPO
Precipio
29.29
13.84
89.58%
BNGO
BioNano Genomics
1.21
-2.64
-68.57%
BDSX
Biodesix
28.48
19.55
218.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.